Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 19Tumor-Agnostic 6Sarcoma 6Gastrointestinal 3Genitourinary 2NET 1Lymphoid 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 13Pheochromocytoma 6Carcinoma, Neuroendocrine 6Somatostatinoma 5Paraganglioma 4Pituitary Neoplasms 3Insulinoma 3Glucagonoma 3Gastrinoma 3Zollinger-Ellison Syndrome 2Vipoma 2Paraganglioma, Extra-Adrenal 2Pancreatic Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Medullary 2Carcinoma, Islet Cell 2Carcinoid Tumor 2Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Rhabdoid Tumor 1Prolactinoma 1Optic Nerve Glioma 1Oligodendroglioma 1Non functioning pancreatic endocrine tumor 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1

Interventions

Everolimus 6Sunitinib 4Octreotide 4Leucovorin 4dabrafenib 3Fluorouracil 33-Iodobenzylguanidine 3trametinib 2selpercatinib 2lutetium Lu 177 dotatate 2avelumab 2alectinib 2PM 01183 2Oxaliplatin 2Irinotecan 2Fulvestrant 2Drug Therapy 2Doxorubicin 2Cisplatin 2trifluridine tipiracil drug combination 1tipifarnib 1telotristat ethyl 1surufatinib 1somapacitan 1ribociclib 1repotrectinib 1pralsetinib 1pentetreotide 1pegfilgrastim 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Temozolomide × Endocrine × Clear all
NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡